InvestLog
LIPO logo

LIPO

Lipella Pharmaceuticals Inc.NASDAQHealthcare
$0.02-0.45%ClosedMarket Cap: $101,658

As of 2026-04-04

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.07

P/S

0.59

EV/EBITDA

0.28

DCF Value

$-9.85

FCF Yield

-2312584.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

-1954.7%

Operating Margin

-3115.2%

Net Margin

-3069.0%

ROE

-208.4%

ROA

-226.8%

ROIC

-308.8%

Financials

View All
PeriodRevenueNet IncomeEPS
Q3 2025$0.00$-1.3M$-0.28
Q2 2025$0.00$-1.3M$-0.31
Q1 2025$0.00$-1.3M$-0.64
Q4 2024$173.7K$-1.4M$-1.37

Trading Activity

Insider Trades

View All
Kaufman Jonathan Hdirector, 10 percent owner, officer: See remarks below.
SellMon Apr 07
Kaufman Jonathan Hdirector, 10 percent owner, officer: See remarks below.
SellMon Apr 07
Kaufman Jonathan Hdirector, 10 percent owner, officer: See remarks below.
SellMon Mar 17
Kaufman Jonathan Hdirector, 10 percent owner, officer: See remarks below.
SellMon Mar 17
Kaufman Jonathan Hdirector, 10 percent owner, officer: See remarks below.
SellTue Mar 11

Company Info

Sector

Healthcare

Industry

—

Country

US

Exchange

NASDAQ

Beta

0.31

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Peers

ARTLAZTRDRMAGTBPINDPNKGNPBMPTIX